What is Liver Cancer?

Liver cancers are malignant tumors that grow on the surface or inside of the liver. Liver tumors are discovered on medical imaging equipment (often by accident) or present themselves symptomatically as an abdominal mass, abdominal pain, jaundice, nausea or liver dysfunction.  Liver cancers should not be confused with liver metastases, which are cancers that originate from organs elsewhere in the body and migrate to the liver.

Risk Factors of Liver Cancer

Cirrhosis, excessive alcohol consumption, or chronic Hepatitis B infection can lead to liver cancer.  Also, men are more likely than woman to have liver cancer, and liver cancer tends to occur at a younger age – between 20 and 50.

Symptoms of Liver Cancer

Symptoms are as follows: Sweating, jaundice, abdominal pain, weight loss, hepatomegaly, abdominal mass, emesis, anemia, back pain, itching, and fever.

Diagnosis of Liver Cancer

An ultrasonographic examination or CT scan with or without contrast of the liver is an excellent screening tool. Magnetic resonance imaging (MRI) can also provide detailed information. Biopsies give the most accurate diagnosis.

Treatment Options for Liver Cancer at FROS Radiation Oncology Cyberknife Center:

At FROS Radiation Oncology Cyberknife Center, our team is committed to bringing leading-edge technology with highly compassionate care to our patients.

Please call us at 1-888-880-6646 today to find the right treatment for you.




August 28, 2013

June 1, 2013

FROS attending physicians, Alan Katz and Josephine Kang, to give an oral presentation at this year's ASTRO meeting on long term outcomes after stereotactic body radiation therapy (SBRT) for prostate cancer.


The Redefining Radiosurgery Video gives definitive clinical, hospital and patient benefits as compared to other radiation therapy and systems.



Flushing: 40-22 Main St, 4th Fl,
Flushing, NY 11354
Brooklyn: 1737 Bath Ave
Brooklyn, NY 11214
Manhattan: 47 Essex St.
New York, NY 10002


Stay in touch with FROS Radiation Oncology & Cyberknife Centers. Join us on Facebook, Twitter and LinkedIn for latest news and info.